|
2025
|
G/S
|
Pharmaceutical preparations for the treatment of cardiovascular, metabolic, and renal diseases an... |
|
|
G/S
|
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of... |
|
|
G/S
|
Pharmaceutical preparations and substances for the treatment
of respiratory diseases and disorders. |
|
|
G/S
|
Pharmaceutical preparations and substances. |
|
|
G/S
|
Pharmaceutical preparations and substances for the treatment of cardiovascular, metabolic, and re... |
|
|
G/S
|
Pharmaceutical preparations and substances |
|
2024
|
G/S
|
Pharmaceutical preparations and substances. |
|
|
Invention
|
Pharmaceutical compositions comprising (2s)-n-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-... |
|
|
G/S
|
Pharmaceutical preparations and substances for the treatment of respiratory diseases and disorders |
|
|
Invention
|
Londamocitinib for the treatment of asthma. A compound of Formula (I) or a pharmaceutically accep... |
|
|
Invention
|
Predicting response to neoadjuvant treatment in non-small cell lung cancer. The disclosure relate... |
|
|
G/S
|
Pharmaceutical preparations and substances for the treatment of respiratory diseases and disorders |
|
|
Invention
|
Treatment of skin disease. The disclosure relates to methods and compositions for the treatment o... |
|
|
Invention
|
T cell binding compositions and methods. The disclosure generally relates to binding proteins tha... |
|
|
Invention
|
T cell binding compositions and methods.
The disclosure generally relates to binding proteins th... |
|
|
Invention
|
Pharmaceutical compositions comprising azd9291.
The present invention relates to pharmaceutical ... |
|
|
Invention
|
Therapeutic combinations comprising anti-steap2 chimeric antigen receptor t cells.
The disclosur... |
|
|
Invention
|
Compounds and methods for reducing psd3 expression. Provided are double-stranded oligonucleotides... |
|
|
Invention
|
Il-5r-alpha antibodies for treating eosinophilic granulomatosis with polyangiitis. Provided herei... |
|
|
Invention
|
Treatment of gastric cancer and/or gastroesophageal junction cancer.
The disclosure relates to m... |
|
|
Invention
|
Treatment of gastric cancer and/or gastroesophageal junction cancer. The disclosure relates to me... |
|
|
Invention
|
Cell therapy. Populations of cells for use in the treatment of heart disease and methods of makin... |
|
|
Invention
|
Azd1390, or a pharmaceutically acceptable salt thereof, in combination with radiation for use in ... |
|
|
Invention
|
Amido heteroaromatic compounds.
The specification relates to compounds of Formula (I):
The spe... |
|
|
Invention
|
Therapeutic combinations comprising anti-steap2 chimeric antigen receptor t cells. The disclosure... |
|
|
Invention
|
Pharmaceutical composition.
The invention concerns pharmaceutical compositions containing a hydr... |
|
|
G/S
|
Pharmaceutical preparations and substances for use in oncology. |
|
|
G/S
|
Pharmaceutical preparations and substances for use in
oncology. |
|
|
Invention
|
Anti-pd-l1 antibodies in combinations with one or more chemotherapy agents for treating endometri... |
|
|
G/S
|
Pharmaceutical preparations and substances for use in oncology |
|
|
Invention
|
Conjugates comprising cleavable linkers.
The specification relates to conjugates comprising a li... |
|
|
Invention
|
Compound azd5462 for use in the treatment of heart failure. The present disclosure relates to dos... |
|
|
Invention
|
Conjugates comprising cleavable linkers. The specification relates to conjugates comprising a lin... |
|
|
Invention
|
Crystalline irak4 inhibitors. NRrRNHNSrSNHH-indazole-5-carboxamide (Compound (II)). |
|
|
Invention
|
Anthracycline derivatives and conjugates and uses thereof. The specification relates to anthracyc... |
|
|
G/S
|
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations and substances for t... |
|
|
Invention
|
Cd123 antibody-drug conjugates and methods of using the same.
The present disclosure generally r... |
|
|
Invention
|
Cd123 antibody-drug conjugates and methods of using the same. The present disclosure generally re... |
|
|
Invention
|
Multivalent cargo-carrying complexes and uses thereof.
Provided are multivalent saccharide-conta... |
|
|
Invention
|
Multivalent cargo-carrying complexes and uses thereof. Provided are multivalent saccharide-contai... |
|
|
Invention
|
Treatment of neurodegenerative diseases. The invention relates to a method of treating or prevent... |
|
|
Invention
|
Rsv vaccine.
Provided herein is a vaccine against RSV. The vaccine comprises an mRNA encoding a ... |
|
|
Invention
|
Rsv vaccine. Provided herein is a vaccine against RSV. The vaccine comprises an mRNA encoding a s... |
|
|
Invention
|
Modified cell. Provided are hypoimmunogenic cells and methods of manufacturing such. |
|
|
Invention
|
Lilrb2 binding proteins and uses thereof. The present disclosure relates to binding proteins (e.g... |
|
|
G/S
|
Pharmaceutical preparations and substances for use in oncology; Pharmaceutical preparations and s... |
|
|
G/S
|
Pharmaceutical preparations and substances for the treatment of respiratory diseases and disorders. |
|
|
Invention
|
Egfr tkis for use in the treatment of non-small lung cancer.
The specification relates to epider... |
|
|
Invention
|
Compositions and methods for improving the efficacy of cas9-based knock-in strategies.
The prese... |
|
|
Invention
|
Combination of egfr inhibitor and mek inhibitor for use in the treatment of nras mutated cancer. ... |
|
2023
|
Invention
|
Anti-ifnar1 antibodies with reduced fc ligand affinity.
The invention provides anti-IFNAR1 antib... |
|
|
Invention
|
Methods of treating prediabetes or reducing the risk of developing type 2 diabetes with dapaglifl... |
|
|
Invention
|
Methods of improving protein expression.
The present disclosure relates to nucleic acids that co... |
|
2022
|
Invention
|
Methods of treating brain tumours and neuroblastomas.
The present disclosure relates to methods ... |
|
|
Invention
|
Compositions, methods and systems for aerosol drug delivery.
1. A pharmaceutical composition del... |
|
|
Invention
|
Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators.
There are disclosed certain 3-a... |
|
|
Invention
|
Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4-b]pyrazines as glp-1 receptor modula... |
|
|
Invention
|
Treatment of lupus.
The disclosure relates to methods and compositions for the treatment of Syst... |
|
|
Invention
|
Combinations with modulators of pnpla3 expression.
Provided are methods of treating a liver dise... |
